obesity

GLP-1 drugs like Ozempic and Wegovy were originally positioned as treatments for obese patients under medical care. A STAT analysis argues they are now marketed as lifestyle products for consumers seeking weight loss, cosmetic benefits and wellness, with telehealth platforms and direct-to-consumer advertising driving demand far beyond traditional clinical settings.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

India has proposed banning junk food sales in school canteens and within 50 meters of schools, aiming to curb rising obesity and diabetes rates among children. The measures would restrict children's access to sugary drinks, chips and other unhealthy products during school hours and nearby, as health officials respond to growing concerns over childhood obesity across the country.

New research suggests the weight-loss drugs Zepbound and Mounjaro may activate brown fat, a type of body tissue that burns calories to generate heat. If confirmed, the findings could help explain part of how the medications drive weight loss beyond appetite suppression, and point to new ways of boosting metabolism in obesity treatment.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New research suggests that weight regained after dieting may be driven by brain biology rather than simply a lack of willpower, pointing to neural mechanisms that push the body back toward its previous weight after a diet ends. The findings are being discussed as a possible shift in how obesity and dieting failure are understood, with implications for treatment and public attitudes toward weight loss.

A new study suggests that removing ultra-processed food from school menus will be a difficult task. The finding highlights practical obstacles schools face in offering fresher, less processed meals to pupils. The research is drawing attention amid growing public and political concern over ultra-processed food in children's diets and its links to obesity and poor health outcomes.

Eli Lilly has announced the Lilly Change the Course Commitment, a new initiative aimed at narrowing treatment gaps in diabetes and obesity care in low- and middle-income countries. The pharmaceutical company says the programme will focus on expanding access to treatment where need is greatest. Details on funding and specific country plans have not yet been widely reported.

Major food companies in India are urging regulators to reconsider the red colour proposed for warning labels on packaged foods, Reuters reports. The industry argues the red symbol could stigmatise products, while health advocates support strong front-of-pack warnings to combat rising obesity, diabetes and high salt, sugar and fat consumption in the country.

Efforts to ban ultra-processed foods from public schools are running into significant practical obstacles, according to reporting highlighted by News-Medical. Schools face challenges around sourcing affordable alternatives, reworking contracts with food suppliers, and meeting nutrition standards on tight budgets. The debate touches on children's health, obesity prevention, and the feasibility of overhauling cafeteria menus at scale.

New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.